Latest news
Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties - simplywall.stsimplywall.st · Thu, 06 Aug 2026 06:42:42 GMTACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales - The Globe and MailThe Globe and Mail · Wed, 05 Aug 2026 16:50:00 GMTNeuren Pharma Shares Jump 16% to Lead ASX 200: The Latest - thebull.com.authebull.com.au · Wed, 05 Aug 2026 09:58:07 GMTNeuren reports record DAYBUE sales as royalties rise and global expansion nears - BiotechDispatchBiotechDispatch · Wed, 05 Aug 2026 09:32:35 GMTNeuren Pharmaceuticals (ASX:NEU) Soars on Record DAYBUE Sales and Upgraded Royalty Forecast - KalkineKalkine · Wed, 05 Aug 2026 08:06:00 GMTNEU:ASX Announcement - Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded - 05 Aug 2026 - Market IndexMarket Index · Wed, 05 Aug 2026 04:11:25 GMTNeuren Rockets on Record DAYBUE Sales as 2026 Royalty Guidance Jumps - KalkineKalkine · Wed, 05 Aug 2026 03:21:00 GMTNeuren Pharmaceuticals Reports Record Q2 DAYBUE Sales, Upgrades Full-Year Royalty Forecast - SharecafeSharecafe · Wed, 05 Aug 2026 01:00:30 GMT